Safety of tildrakizumab in patients with preexisting metabolic syndrome: Long-term data from the post hoc analysis of two phase 3 clinical studies (reSURFACE 1 and reSURFACE 2)

被引：0
|
作者：
Lebwohl, Mark G. [1 ]
Mehta, Nehal N. [2 ]
Gottlieb, Alice B. [2 ]
Mendelsohn, Alan M. [3 ]
Parno, Jeff [3 ]
Rozzo, Stephen J. [4 ]
Menter, M. Alan [5 ]
机构：
[1] Mt Sinai Hosp, Dept Dermatol, New York, NY 10029 USA
[2] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[3] Sun Pharmaceut, Mumbai, Maharashtra, India
[4] Sun Pharmaceut Ind, Mumbai, Maharashtra, India
[5] Baylor Scott & White, Dallas, TX USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2020年 / 83卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
15960
引用
收藏
页码：AB51 / AB51
页数：1
相关论文
共 50 条
  • [21] Long-term efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who were partial responders or nonresponders to etanercept: Post hoc analysis through 5 years from the reSURFACE 2 phase 3 trial
    Thaci, Diamant
    Griffiths, Christopher E. M.
    Iversen, Lars
    Peserico, Andrea
    Pau-Charles, Ignasi
    Blauvelt, Andrew
    Reich, Kristian
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB119 - AB119
  • [22] Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials
    Reich, Kristian
    Papp, Kim A.
    Blauvelt, Andrew
    Tyring, Stephen K.
    Sinclair, Rodney
    Thaci, Diamant
    Nograles, Kristine
    Mehta, Anish
    Cichanowitz, Nicole
    Li, Qing
    Liu, Kenneth
    La Rosa, Carmen
    Green, Stuart
    Kimball, Alexa B.
    LANCET, 2017, 390 (10091): : 276 - 288
  • [23] The maintenance of effect with tildrakizumab over 5 years is independent of baseline characteristics: pooled analysis of the phase 3 studies reSURFACE 1 and reSURFACE 2 in patients with moderate to severe psoriasis
    Thaci, Diamant
    Piaserico, Stefano
    Diemert, Sebastian
    Torres, Tiago
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 60 - 60
  • [24] Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks (vol 182, pg 605, 2020)
    Reich, K.
    Warren, R. B.
    Iversen, L.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 (01) : 131 - 132
  • [25] Efficacy of tildrakizumab in patients with moderate to severe psoriasis according to disease duration: Pooled analysis from reSURFACE 1 and reSURFACE 2 phase 3 trials at week 28
    Thaci, Diamant
    Iversen, Lars
    Pau-Charles, Ignasi
    Schoenenberger Lopez, Andreu
    Blauvelt, Andrew
    Puig, Lluis
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB160 - AB160
  • [26] Efficacy and safety of long-term tildrakizumab for moderate to severe chronic plaque psoriasis: 3-year results from reSURFACE 2
    Gooderham, M.
    Papp, K.
    Blauvelt, A.
    Thaci, D.
    Li, Q.
    Mendelsohn, A.
    Parno, J.
    Reich, K.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2019, 60 : 61 - 62
  • [27] Efficacy and safety of long-term tildrakizumab for moderate to severe chronic plaque psoriasis: 3-year results from reSURFACE 1
    Tyring, S.
    Spelman, L.
    Igarashi, A.
    Ohtsuki, M.
    Li, Q.
    Mendelsohn, A.
    Parno, J.
    Guenthner, S.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2019, 60 : 61 - 61
  • [28] Insights into the efficacy and safety of tildrakizumab in patients with moderate-to-severe plaque psoriasis across age quartiles: Pooled analyses from the Phase 3 reSURFACE 1 and reSURFACE 2 trials
    Elewski, Boni
    Han, George
    Rozzo, Stephen J.
    Gogineni, Ranga
    Schenkel, Brad
    Guenthner, Scott
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB57 - AB57
  • [29] Long-term efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 5-year extension of a phase 3 study (reSURFACE 1)
    Imafuku, Shinichi
    Nakagawa, Hidemi
    Igarashi, Atsuyuki
    Morita, Akimichi
    Okubo, Yukari
    Sano, Shigetoshi
    Tada, Yayoi
    Nemoto, Osamu
    Rozzo, Stephen J.
    Kawamura, Masaki
    Ohtsuki, Mamitaro
    JOURNAL OF DERMATOLOGY, 2021, 48 (06): : 844 - 852
  • [30] Long-term efficacy of tildrakizumab 100 mg by PASI 75/90/100 and PGA in a pooled analysis of reSURFACE 1 and reSURFACE 2 through up to 4 years of treatment
    Jackson, J. Mark
    Alexis, Andrew
    Kucera, Kristine
    Mendelsohn, Alan M.
    Rozzo, Stephen J.
    Gorelick, Joseph
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB79 - AB79
12345